|
Name |
N-(2,3-Dimethylphenyl)-2-((4-phenyl-1H-imidazol-2-yl)thio)acetamide
|
Molecular Formula | C19H19N3OS | |
IUPAC Name* |
N-(2,3-dimethylphenyl)-2-[(5-phenyl-1H-imidazol-2-yl)sulfanyl]acetamide
|
|
SMILES |
CC1=C(C(=CC=C1)NC(=O)CSC2=NC=C(N2)C3=CC=CC=C3)C
|
|
InChI |
InChI=1S/C19H19N3OS/c1-13-7-6-10-16(14(13)2)21-18(23)12-24-19-20-11-17(22-19)15-8-4-3-5-9-15/h3-11H,12H2,1-2H3,(H,20,22)(H,21,23)
|
|
InChIKey |
MVBJAPWJNOFGMS-UHFFFAOYSA-N
|
|
Synonyms |
312278-95-8; N-(2,3-Dimethylphenyl)-2-((4-phenyl-1H-imidazol-2-yl)thio)acetamide; N-(2,3-dimethylphenyl)-2-[(4-phenyl-1H-imidazol-2-yl)thio]acetamide; Cambridge id 5927802; Oprea1_434997; Oprea1_495745; CHEMBL1398569; HMS1807D17; ZINC4565091; STK735635; ZINC00051853; AKOS000568349; N-(2,3-Dimethyl-phenyl)-2-(4-phenyl-1H-imidazol-2-ylsulfanyl)-acetamide; N-(2,3-dimethylphenyl)-2-[(5-phenyl-1H-imidazol-2-yl)sulfanyl]acetamide; NCGC00102580-01; EU-0018308; AB00101070-01; SR-01000519341; SR-01000519341-1; Acetamide, 2-(4-phenyl-2-imidazolylthio)-N-(2,3-dimethylphenyl)-; N-(2,3-Dimethylphenyl)-2-[(4-phenyl-1H-imidazol-2-yl)sulfanyl]acetamide; N-(2,3-Dimethylphenyl)-2-[(4-phenyl-1H-imidazol-2-yl)sulfanyl]acetamide #
|
|
CAS | NA | |
PubChem CID | 593949 | |
ChEMBL ID | CHEMBL1398569 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 337.4 | ALogp: | 4.2 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 24 | QED Weighted: | 0.648 |
Caco-2 Permeability: | -4.87 | MDCK Permeability: | 0.00002360 |
Pgp-inhibitor: | 0.065 | Pgp-substrate: | 0.029 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.001 |
Blood-Brain-Barrier Penetration (BBB): | 0.388 | Plasma Protein Binding (PPB): | 99.42% |
Volume Distribution (VD): | 0.466 | Fu: | 0.85% |
CYP1A2-inhibitor: | 0.944 | CYP1A2-substrate: | 0.674 |
CYP2C19-inhibitor: | 0.962 | CYP2C19-substrate: | 0.103 |
CYP2C9-inhibitor: | 0.933 | CYP2C9-substrate: | 0.857 |
CYP2D6-inhibitor: | 0.771 | CYP2D6-substrate: | 0.53 |
CYP3A4-inhibitor: | 0.924 | CYP3A4-substrate: | 0.536 |
Clearance (CL): | 10.256 | Half-life (T1/2): | 0.742 |
hERG Blockers: | 0.199 | Human Hepatotoxicity (H-HT): | 0.366 |
Drug-inuced Liver Injury (DILI): | 0.958 | AMES Toxicity: | 0.922 |
Rat Oral Acute Toxicity: | 0.076 | Maximum Recommended Daily Dose: | 0.273 |
Skin Sensitization: | 0.947 | Carcinogencity: | 0.12 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.625 |
Respiratory Toxicity: | 0.948 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001388 | 0.398 | D05FTJ | 0.451 | ||||
ENC001109 | 0.363 | D05UWI | 0.365 | ||||
ENC003390 | 0.355 | D09VXM | 0.347 | ||||
ENC000321 | 0.338 | D0Y7EM | 0.337 | ||||
ENC001352 | 0.337 | D0J6WW | 0.333 | ||||
ENC001307 | 0.333 | D0YB1G | 0.333 | ||||
ENC005445 | 0.326 | D09ZXR | 0.331 | ||||
ENC000732 | 0.318 | D0M9DC | 0.330 | ||||
ENC003342 | 0.317 | D0P3JU | 0.323 | ||||
ENC005446 | 0.313 | D0L6DA | 0.323 |